文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

佐剂在现代疫苗中的关键作用。

Key roles of adjuvants in modern vaccines.

机构信息

Infectious Disease Research Institute, Seattle, Washington, USA.

出版信息

Nat Med. 2013 Dec;19(12):1597-608. doi: 10.1038/nm.3409. Epub 2013 Dec 5.


DOI:10.1038/nm.3409
PMID:24309663
Abstract

Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs. However, many adjuvants fail during product development owing to factors such as manufacturability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns. This Review outlines the potential benefits of adjuvants in current and future vaccines and describes the importance of formulation and mechanisms of action of adjuvants. Moreover, we emphasize safety considerations and other crucial aspects in the clinical development of effective adjuvants that will help facilitate effective next-generation vaccines against devastating infectious diseases.

摘要

新型佐剂配方的疫苗越来越多地进入到高级开发和许可阶段,为满足以前未满足的临床需求提供了新工具。然而,由于可制造性、稳定性、效力不足、不可接受的耐受性水平或安全性问题等因素,许多佐剂在产品开发过程中失败。本综述概述了佐剂在当前和未来疫苗中的潜在益处,并描述了佐剂的配方和作用机制的重要性。此外,我们强调了在有效佐剂的临床开发中安全性方面的考虑因素和其他关键方面,这将有助于促进针对破坏性传染病的下一代有效疫苗。

相似文献

[1]
Key roles of adjuvants in modern vaccines.

Nat Med. 2013-12-5

[2]
The path to a successful vaccine adjuvant--'the long and winding road'.

Drug Discov Today. 2009-3-5

[3]
Vaccine adjuvants: smart components to boost the immune system.

Arch Pharm Res. 2017-10-13

[4]
Microparticles as vaccine adjuvants and delivery systems.

Expert Rev Vaccines. 2003-4

[5]
An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.

Expert Rev Vaccines. 2017-5

[6]
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.

Curr Opin Immunol. 2011-4-19

[7]
Application of plant-derived products as adjuvants for immune activation and vaccine development.

Vaccine. 2024-11-14

[8]
Flagellin as a vaccine adjuvant.

Expert Rev Vaccines. 2018-3-30

[9]
Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?

Front Immunol. 2018-12-13

[10]
Beyond antigens and adjuvants: formulating future vaccines.

J Clin Invest. 2016-3-1

引用本文的文献

[1]
Co-injection with inactivated and inactivated H1N1 influenza virus intravenously strengthen the protection of H1N1 influenza virus infections in mice.

Front Microbiol. 2025-8-20

[2]
Development and Evaluation of Dual Microneedle Array Patch for Sequential Intradermal Delivery of Adjuvant and Antigen.

Pharm Res. 2025-9-4

[3]
Safety and Toxicology Profile of TT-6-AmHap Heroin Conjugate Vaccine.

Vaccines (Basel). 2025-7-26

[4]
Comparative Analysis of Chitosan, Lipid Nanoparticles, and Alum Adjuvants in Recombinant SARS-CoV-2 Vaccine: An Evaluation of Their Immunogenicity and Serological Efficacy.

Vaccines (Basel). 2025-7-24

[5]
Polyphosphazene-Based Nanotherapeutics.

J Funct Biomater. 2025-8-2

[6]
Modified dipeptide based nanospheres as a potent adjuvating delivery system for recombinant vaccines.

Front Drug Deliv. 2023-4-26

[7]
Biodistribution of the saponin-based adjuvant Matrix-M™ following intramuscular injection in mice.

Front Drug Deliv. 2023-11-6

[8]
Mucosal immunity and vaccination strategies: current insights and future perspectives.

Mol Biomed. 2025-8-20

[9]
Understanding and improving vaccine efficacy in older adults.

Nat Aging. 2025-8

[10]
Modulation of oral vaccine efficacy by the gut microbiota.

NPJ Vaccines. 2025-8-1

本文引用的文献

[1]
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

J Control Release. 2013-8-9

[2]
Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.

BMC Infect Dis. 2013-7-26

[3]
Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A.

Sleep Med. 2013-6-14

[4]
Implications of narcolepsy link with swine-influenza vaccine.

Lancet Infect Dis. 2013-5

[5]
The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.

Hum Vaccin Immunother. 2013-5-31

[6]
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Eur J Immunol. 2013-7-3

[7]
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.

PLoS One. 2013-5-1

[8]
Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.

Int Immunopharmacol. 2013-4-2

[9]
Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination.

Neurology. 2013-3-13

[10]
Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis.

BMJ. 2013-2-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索